Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Tremfya

Tremfya 100 mg OnePress solution for injection in pre-filled pen Tremfya 100 mg PushPen solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 71–72

HOS-137356 · Präparat HOS-098012

71 Based on laboratory assessments, most transaminase increases (ALT and AST) were ≤ 3 x upper limit of normal (ULN). Transaminase increases from > 3 to ≤ 5 x ULN and > 5 x ULN were low in frequency, occurring more often in the guselkumab q4w group compared with the guselkumab q8w group (Table 2). A similar pattern of frequency by severity and by treatment group was observed through the end of the 2-year Phase III psoriatic arthritis clinical study.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.